On January 6, 2022, Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The company applies deep knowledge of 14-3-3 proteins and a proprietary suite of drug discovery tools to create molecular glues that stabilize 14-3-3:target complexes. These molecular glue stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation. Ambagon’s initial focus is on oncology, with five programs in discovery. The financing was led by Nextech Invest.

Wilson Sonsini Goodrich & Rosati advised Ambagon on IP matters related to the Series A transaction and has represented Ambagon in patent matters since the company's inception. The Wilson Sonsini team was led by Deborah Smith and included Mike Hostetler.

For more information, please see Ambagon's press release.